PDUFA
![Iovance Biotherapeutics, FDA, FDA delay, cell therapy, tumor-infiltrating lymphocyte, Prescription Drug User Fee Act Date, PDUFA, melanoma](https://pharmtales.com/wp-content/uploads/2023/09/Iovances-cell-therapy-for-skin-cancer-faces-three-year-delay-due-to-FDA-issues.jpg)
Iovance’s cell therapy for skin cancer faces three-year delay due to FDA issues
Anika Sharma
The FDA has introduced a new twist in the ongoing Iovance Biotherapeutics saga, causing further delays in the approval process ...
The FDA has introduced a new twist in the ongoing Iovance Biotherapeutics saga, causing further delays in the approval process ...
pharmtales
Latest Pharma News & Insights